Taking antithrombic therapy during emergency laparoscopic cholecystectomy for acute cholecystitis does not affect the postoperative outcomes: a propensity score matched study.


Journal

BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567

Informations de publication

Date de publication:
05 Feb 2022
Historique:
received: 27 09 2021
accepted: 27 01 2022
entrez: 5 2 2022
pubmed: 6 2 2022
medline: 9 2 2022
Statut: epublish

Résumé

Continuing antithrombic therapy (ATT) during surgery increases the risk of bleeding. However, it is difficult to discontinue the ATT in emergency surgery. Therefore, safety of emergency laparoscopic cholecystectomy (LC) for acute cholecystitis (AC) is still unclear. We aimed to clarify the affect of ATT during emergency LC for AC. Patients with AC were classified into ATT group (n = 30) and non-ATT group (n = 120). Postoperative outcomes were compared after propensity score matching (n = 22). Higher level of c-reactive protein level and shorter activated partial thromboplastin time (APTT) was observed in ATT group than in non-ATT group after matching. No significant difference was found between other patient characteristics and perioperative results. Blood loss over 100 mL was observed in 8 patients. Multivariate analyze showed that APTT was an independent risk factor for bleeding over 100 mL (P = 0.039), while ACT and APT was not. Taking ATT does not affect the blood loss or complications during emergency LC for AC. Controlling intraoperative bleeding is essential for a safe postoperative outcome.

Sections du résumé

BACKGROUND BACKGROUND
Continuing antithrombic therapy (ATT) during surgery increases the risk of bleeding. However, it is difficult to discontinue the ATT in emergency surgery. Therefore, safety of emergency laparoscopic cholecystectomy (LC) for acute cholecystitis (AC) is still unclear. We aimed to clarify the affect of ATT during emergency LC for AC.
METHODS METHODS
Patients with AC were classified into ATT group (n = 30) and non-ATT group (n = 120). Postoperative outcomes were compared after propensity score matching (n = 22).
RESULTS RESULTS
Higher level of c-reactive protein level and shorter activated partial thromboplastin time (APTT) was observed in ATT group than in non-ATT group after matching. No significant difference was found between other patient characteristics and perioperative results. Blood loss over 100 mL was observed in 8 patients. Multivariate analyze showed that APTT was an independent risk factor for bleeding over 100 mL (P = 0.039), while ACT and APT was not.
CONCLUSIONS CONCLUSIONS
Taking ATT does not affect the blood loss or complications during emergency LC for AC. Controlling intraoperative bleeding is essential for a safe postoperative outcome.

Identifiants

pubmed: 35120469
doi: 10.1186/s12893-022-01501-6
pii: 10.1186/s12893-022-01501-6
pmc: PMC8817483
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

42

Informations de copyright

© 2022. The Author(s).

Références

Scand J Gastroenterol. 2019 Nov;54(11):1357-1363
pubmed: 31718330
J Gastrointest Surg. 2021 Nov;25(11):2939-2947
pubmed: 33754259
Am J Surg. 2015 Apr;209(4):689-94
pubmed: 25064416
World J Surg Oncol. 2019 Jun 1;17(1):92
pubmed: 31153382
Dis Colon Rectum. 2018 Nov;61(11):1306-1315
pubmed: 30239396
Lancet. 2017 Jul 29;390(10093):490-499
pubmed: 28622955
Updates Surg. 2021 Oct;73(5):1767-1774
pubmed: 33582984
Langenbecks Arch Surg. 2012 Feb;397(2):297-306
pubmed: 22048442
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Hepatobiliary Pancreat Sci. 2018 Nov;25(11):518-526
pubmed: 30312537
Clin Interv Aging. 2018 Jan 24;13:133-141
pubmed: 29416321
Clin Interv Aging. 2009;4:165-77
pubmed: 19503778
Br J Haematol. 2003 Nov;123(4):676-82
pubmed: 14616972
Eur J Clin Pharmacol. 2020 Jun;76(6):867-876
pubmed: 32222786
N Engl J Med. 2014 Apr 17;370(16):1494-503
pubmed: 24679062
Am Surg. 2017 May 1;83(5):486-490
pubmed: 28541859
J Am Coll Surg. 2013 Dec;217(6):1044-53
pubmed: 24051069
J Thromb Thrombolysis. 2020 Apr;49(3):492-496
pubmed: 31776847
Ann Transl Med. 2019 Sep;7(Suppl 6):S198
pubmed: 31656777
Minerva Cardioangiol. 2018 Jun;66(3):301-313
pubmed: 29125269
Surg Endosc. 2019 Oct;33(10):3165-3176
pubmed: 31309311
Surg Endosc. 2020 Jul;34(7):2994-3001
pubmed: 31463722
Sci Rep. 2020 Jun 22;10(1):10122
pubmed: 32572122
Blood. 2012 Oct 11;120(15):2954-62
pubmed: 22932800
J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):96-100
pubmed: 29090868
Dig Liver Dis. 2019 Apr;51(4):489-495
pubmed: 30594462
J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):41-54
pubmed: 29032636
Am J Med. 1985 Nov;79(5):552-9
pubmed: 3933340
Asian J Endosc Surg. 2020 Jul;13(3):359-365
pubmed: 31430063
J Anesth. 2019 Feb;33(1):90-95
pubmed: 30483897
Hepatogastroenterology. 2014 Sep;61(134):1501-6
pubmed: 25436333

Auteurs

Kentaro Oji (K)

Department of Surgery, Kita-Harima Medical Center, 926-250 Ichiba-cho, Ono, Hyogo, 675-1392, Japan.

Yasunori Otowa (Y)

Department of Surgery, Kita-Harima Medical Center, 926-250 Ichiba-cho, Ono, Hyogo, 675-1392, Japan. dregg338@hotmail.com.
Radiation Biology Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892, USA. dregg338@hotmail.com.

Yuta Yamazaki (Y)

Department of Surgery, Kita-Harima Medical Center, 926-250 Ichiba-cho, Ono, Hyogo, 675-1392, Japan.

Keisuke Arai (K)

Department of Surgery, Kita-Harima Medical Center, 926-250 Ichiba-cho, Ono, Hyogo, 675-1392, Japan.

Yasuhiko Mii (Y)

Department of Surgery, Kita-Harima Medical Center, 926-250 Ichiba-cho, Ono, Hyogo, 675-1392, Japan.

Keitaro Kakinoki (K)

Department of Surgery, Kita-Harima Medical Center, 926-250 Ichiba-cho, Ono, Hyogo, 675-1392, Japan.

Tetsu Nakamura (T)

Department of Surgery, Kita-Harima Medical Center, 926-250 Ichiba-cho, Ono, Hyogo, 675-1392, Japan.

Daisuke Kuroda (D)

Department of Surgery, Kita-Harima Medical Center, 926-250 Ichiba-cho, Ono, Hyogo, 675-1392, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH